

P1339

¹Department of Dermatology & Academic Wound Healing, Division of Infection and Immunity, Cardiff University, Cardiff, UK; ²Department of Dermatology, Wayne State University School of Medicine, Detroit, Michigan, USA; ³Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, Florida, USA; ⁴Department of Maxillofacial Surgery, Papanikolaou General Hospital of Thessaloniki, Aristotle University of Thessaloniki, Thessaloniki, Greece; ⁵European Hidradenitis Suppurativa Foundation (EHSF) e.V., Dessau, Germany; ⁶Department of Dermatology, Edouard Herriot Hospital, Hospices Civils de Lyon, Claude Bernard Lyon I University, Lyon, France; ⁷Department of Dermatology, University of the Ryukyus Graduate School of Medicine, Okinawa, Japan; ⁸UCB, Courbevoie, France; ⁹UCB, Breda, The Netherlands; ¹⁰UCB, Monheim am Rhein, Germany; ¹¹UCB, Slough, UK; ¹²Beth Israel Deaconess Medical Center, Department of Dermatology, Harvard Medical School, Boston, Massachusetts, USA

To evaluate the long-term maintenance of efficacy and health-related quality of life (HRQoL) responses over 3 years in patients who achieved a high level of response after 1 year of bimekizumab treatment.

- Hidradenitis suppurativa (HS) is a chronic, progressive, inflammatory skin disease with a substantial cumulative disease burden, leading to impairment of patients' HRQoL.^{1,2}
- Bimekizumab, a humanised IgG1 monoclonal antibody that selectively inhibits interleukin (IL)-17F in addition to IL-17A, has demonstrated efficacy in phase 3 clinical trials.^{3,4}
- It is important to assess the long-term maintenance of clinical efficacy and HRQoL, as well as patient-reported outcomes, in patients treated with bimekizumab.

- Data were pooled from the BE HEARD I&II trials (NCT04242446, NCT04242498) and their open-label extension, BE HEARD EXT (NCT04901195) for patients with moderate to severe HS.^{4,5}
 - Data are reported for patients randomised to bimekizumab 320 mg from baseline in BE HEARD I&II who entered BE HEARD EXT and continued to receive bimekizumab.
 - Included patients in this analysis were those who had either clinical efficacy or patient-reported outcome (HRQoL and skin pain) responses at Year 1 (Week 48).
- Maintenance of efficacy, as measured by the International Hidradenitis Suppurativa Severity Score System (IHS4)-55/75/90/100, is reported from Year 1 to Year 3 (Week 148) in patients with an IHS4-55/75/90/100 response at Year 1.
 - IHS4-55/75/90/100 was defined as an improvement of $\geq 55\%/75\%/90\%/100\%$ in IHS4 from baseline.
- Maintenance of HRQoL response, assessed via Hidradenitis Suppurativa Quality of Life (HiSQoL, score range 0–68) and Dermatology Life Quality Index (DLQI, score range 0–30), is reported through 3 years in patients with a HiSQoL or DLQI response at Year 1, respectively.
 - HiSQoL response was defined as total score ≤ 4 (no impact of HS on HRQoL) or total score ≤ 14 (no/mild impact of HS on HRQoL).
 - DLQI response was defined as DLQI 0/1 (HS has no effect on a patient's life) or DLQI 0–5 (HS has no/small effect on a patient's life).
- Maintenance of skin pain response, defined as $\geq 30\%$ reduction and ≥ 1 -point decrease from baseline in the Hidradenitis Suppurativa Symptom Questionnaire (HSSQ, score range 0–10) skin pain score, is evaluated through 3 years in patients with an HSSQ skin pain response at Year 1.
- Data are reported as observed case (OC).


- Of the 1,014 patients in the BE HEARD I&II trials, 868 were randomised to bimekizumab at baseline; 556 patients completed Year 1 and entered BE HEARD EXT.

- At Year 1, 75.5% (420/556), 58.8% (327/556), 41.2% (229/556) and 25.2% (140/556) of patients achieved IHS4-55/75/90/100, respectively (**Figure 1**).
 - High proportions of these patients maintained IHS4-55/75/90/100 response from Year 1 to Year 3.
 - Notably, over 70% maintained their IHS4-100 response (total resolution of inflammatory lesions) to Year 3.

- Of patients with no impact (33.3% [185/555]) or no/mild impact (72.8% [404/555]) of HS on their HRQoL at Year 1, 73.0% and 87.5% maintained their HISQL response at Year 3, respectively (**Figure 2**).
- Of patients with a DLQI score of 0/1 at Year 1 (27.4% [151/551]), 70.3% maintained this response at Year 3 (**Figure 3**).
 - Similarly, of the patients with a DLQI score of 0–5 at Year 1 (68.2% [376/551]), 86.3% maintained their response at Year 3 (**Figure 3**).
- Most patients (91.8%) maintained their HSSQ skin pain response to Year 3 (**Figure 4**).

Among Year 1 responders, clinical efficacy and patient-reported pain and HRQoL outcome responses were maintained to Year 3, supporting the long-term use of bimekizumab in patients with HS.

Maintenance of response at Year 3 in Year 1 responders



High-level responses for **clinical efficacy** and **patient-reported outcomes** achieved at Year 1 were **maintained** through 3 years of **bimekizumab treatment**

Proportion of patients achieving IHS4-55/75/90/100 response at Year 1:

IHS4-55: 75.5%

IHS4-75: 58.8%

IHS4-90: 41.2%

IHS4-100: 25.2%

IHS4-55/75/90/100 maintenance of response, % (n/N)

Legend: IHS4-55 (Blue), IHS4-75 (Green), IHS4-90 (Red), IHS4-100 (Orange)

Week

Year 1 (Weeks 48-92):

- IHS4-55: 91.4% (318/348)
- IHS4-75: 85.2% (236/277)
- IHS4-90: 70.8% (136/192)
- IHS4-100: 62.9% (73/116)

Year 2 (Week 96):

- IHS4-55: 91.4% (318/348)
- IHS4-75: 85.2% (236/277)
- IHS4-90: 70.8% (136/192)
- IHS4-100: 62.9% (73/116)

Year 3 (Weeks 108-148):

- IHS4-55: 94.4% (268/284)
- IHS4-75: 89.0% (202/227)
- IHS4-90: 76.9% (123/160)
- IHS4-100: 72.0% (67/93)

OC, n/N: N represents number of patients with a non-missing lesion count assessment in the given week, and percentages are calculated accordingly. Data are reported for patients who achieved IHS4-55/75/90/100 at Year 1 of BE HEARD I/II. At Week 48, n/N values for IHS4-55/75/90/100 responders were as follows: IHS4-55: 420/556; IHS4-75: 327/556; IHS4-90: 229/556; IHS4-100: 140/556.

Proportion of patients achieving HISQOL response at Year 1:

HISQOL total score ≤ 4 : 33.3%

HISQOL total score ≤ 14 : 72.8%

HISQOL total score maintenance of response, % (n/N)

Week

Year 1 Year 2 Year 3

Week	HISQOL ≤ 4 (%)	HISQOL ≤ 4 (n/N)	HISQOL ≤ 14 (%)	HISQOL ≤ 14 (n/N)
48 (Year 1)	100	100/100	100	100/100
64	74	74/100	88	88/100
80	80	80/100	88	88/100
96 (Year 2)	72.3	112/155	89.6	303/338
108	73	73/100	89	89/100
124	73	73/100	86	86/100
140	77	77/100	89	89/100
148 (Year 3)	73.0	92/126	87.5	239/273

OC, n/N: N represents number of patients with a non-missing assessment in the given week, and percentages are calculated accordingly. Data are reported for patients who achieved HiSQoL total score ≤ 4 and ≤ 14 (no or no/mild impact of HS on HRQoL, respectively) at Year 1 of BE HEARD I&II. At Week 48, n/N values for HiSQoL total score ≤ 4 and ≤ 14 responders were as follows: HiSQoL total score ≤ 4 : 185/555; HiSQoL total score ≤ 14 : 404/555.

Proportion of patients achieving DLQI response at Year 1:

DLQI 0/1: 27.4%

DLQI 0-5: 68.2%

DLQI total score maintenance of response, % (n/N)

Legend: DLQI 0-5 (Green line), DLQI 0-1 (Blue line)

Week	DLQI 0-5 (%)	DLQI 0-5 (n/N)	DLQI 0-1 (%)	DLQI 0-1 (n/N)
48 (Year 1)	100		100	
64	82		72	
80	87		73	
96 (Year 2)	84.3	263/312	69.5	89/128
108	86		65	
124	83		65	
140	84		73	
148 (Year 3)	86.3	215/249	70.3	71/101

OC, n/N: N represents number of patients with a non-missing assessment in the given week, and percentages are calculated accordingly. Data are reported for patients who achieved DLQI total score 0/1 and 0–5 at Year 1 of BE HEARD I6II. At Week 48, n/N values for DLQI 0/1 and 0–5 responders were as follows: DLQI 0/1: 151/551; DLQI 0–5: 376/551.

The figure displays the maintenance of HSSQ skin pain response over a 148-week period. A line graph plots the percentage of patients maintaining their response, with data points at weeks 48, 64, 80, 96, 108, 124, 140, and 148. A donut chart inset highlights the initial 72.2% response rate at Year 1. The graph shows a slight decrease in response maintenance over time, with a final value of 91.8% at Week 148.

Week	HSSQ skin pain response (%)	n/N
48 (Year 1)	100	-
64	89.7	262/292
80	89.7	-
96 (Year 2)	89.7	262/292
108	89.7	-
124	90.0	-
140	90.0	-
148 (Year 3)	91.8	225/245

OC, n/N: N represents number of patients with a non-missing assessment in the given week, and percentages are calculated accordingly. Data are reported for patients who achieved $\geq 30\%$ reduction and a 1-point decrease from baseline in HSSQ skin pain score at Year 1 of BE HEARD I&II. At Week 48, n/N values for HSSQ skin pain response were 358/496.

DLQI: Dermatology Life Quality Index; **HISQOL:** Hidradenitis Suppurativa Quality of Life; **HRQoL:** health-related quality of life; **HS:** hidradenitis suppurativa; **HSSQ:** Hidradenitis Suppurativa Symptom Questionnaire; **IHS4:** International Hidradenitis Suppurativa Severity Score System; **IL:** interleukin; **OC:** observed case; **OLE:** open-label extension.

References: Kaur AP et al. *Skin Health Dis* 2023;5:214. | Montenegro-Vilchez T et al. *Avicenn Res Public Health* 2021;18:679. | Adams R et al. *Front Immunol* 2020;11:1894. | Kimball AB et al. *Lancet* 2024;403:2504–19. | Sayed CJ et al. *J Am Acad Dermatol* 2024;96:867–78. **Author Contributions:** Substantial contributions to study conception/design, or acquisition/analysis/interpretation of data: **JRI, SD, HL-T, AK, AV, SJ, EV, BH, NT, MLP**. Drafting of the publication, or reviewing it critically for important intellectual content: **JRI, SD, HL-T, AK, AV, SJ, EV, BH, NT, MLP**. Final approval of the publication: **JRI, SD, HL-T, AK, AV, SJ, EV, BH, NT, MLP**. **Disclosures:** JRI: Received a stipend as immediate past-Editor-in-Chief of the British Journal of Dermatology and an authorship honorarium from UpToDate; consultant for AbbVie, Bluebird bio, Boehringer Ingelheim, Cantargia, ChemCentryr, Cytiryl, Eisai, Genentech, Incyte, Indego, Inosmed, Janssen, Karyopharm, Loxo, Novartis, Novartis Oncology, Novartis Pharmaceuticals, Novartis Vaccines and Biologics, Pfizer, Regeneron, Sanofi, and UCB. HL-T: GLASS, Hidradenitis Suppurativa Investigator Global Assessment (HS-IGA) and Patient Global Assessment instruments for HS; department receives income from copyright of the Dermatology Life Quality Index (DLQI) and related instruments. **SD:** Speaker for AbbVie, Novartis and UCB; consultant for AbbVie, Novartis and UCB; research grants from AbbVie, Incyte, Inosmed, MoonLake Immunotherapeutics, Pfizer, Regeneron, Sanofi and UCB. **AK:** Declares no conflicts of interest. **AV:** Personal fees from AbbVie, Amgen, Bristol Myers Squibb, Eli Lilly and Company, Janssen, LEO Pharma, MSD, Novartis and Regeneron. **EV:** Personal fees from AbbVie, Amgen, Bristol Myers Squibb, Eli Lilly and Company, Janssen, LEO Pharma, MSD, Novartis and Regeneron. **BH:** Personal fees from AbbVie, Amgen, Bristol Myers Squibb, Eli Lilly and Company, Janssen, LEO Pharma, MSD, Novartis and Regeneron. **NT:** Personal fees from AbbVie, Amgen, Bristol Myers Squibb, Eli Lilly and Company, Janssen, LEO Pharma, MSD, Novartis and Regeneron. **MLP:** Consultant and investigator for AbbVie, Arcutis, Arista Therapeutics, Avalo Therapeutics, Eli Lilly and Company, Incyte, Janssen, Merck, MoonLake Immunotherapeutics, Navigator Biosciences, Novartis, Pfizer, Prometheus, Sanofi, Sonoma Biotherapeutics, UCB, Vertex and Zura Bio; consultant for Almirall, IDEC, Inosmed, Orkva, Otsuka, Propeller Biosciences, Spyre and Trifecta Clinical/WCG; investigator for AnaptysBio, Bayer, Bristol Myers Squibb, OASIS Pharmaceuticals and Regeneron; received royalties from Beth Israel Deaconess Medical Center, received fellowship funding to institution from AbbVie. **Acknowledgements:** These studies were funded by UCB. We thank the patients and their caregivers in addition to the investigators and their teams who contributed to this study. The authors also thank Susana Lobo Berastegui, MScI, of UCB, for her contribution to the manuscript.



To receive a copy of this poster and the study design figure, scan the QR code.
Link expiration: 1 January 2027